Eli Lilly and Co LLY
News
7 healthcare stocks that stand out as investors pay up for the sector
7 healthcare stocks that stand out as -2-
Eli Lilly on Track for Record High Close — Data Talk
Correction to Eli Lilly's Omvoh Hits Goal in Phase 3 Study Article on Oct. 19
Metis TechBio in Discovery Pact Potentially Worth More Than $1 Billion With Eli Lilly
Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
EMA Recommends Granting Marketing Authorization to Eli Lilly Weight-Loss Drug
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
Lilly confirms date and conference call for third-quarter 2026 financial results announcement
Adlai Nortye to Work With Eli Lilly, Merck on Trial for Cancer Treatment
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Nasdaq and S&P Hold Weekly Gains as Small Caps and Dow Slip Midweek
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief — Update


